Understanding how pancreatic cancer resists treatment with trametinib and 4-aminoquinolones.
Resistance Mechanisms to Combined Trametinib and 4-aminoquinolones in the Inhibition of Pancreatic Cancer
This study is looking at how pancreatic cancer cells can avoid being killed by certain drugs, with the hope of finding ways to make treatments more effective for patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10857314 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which pancreatic cancer cells resist treatment with trametinib and 4-aminoquinolones, which are drugs used to target specific pathways involved in cancer growth. By studying these resistance mechanisms, the research aims to identify predictive biomarkers that could help tailor treatments for patients. The approach includes both laboratory experiments and clinical trials, where the effectiveness of the drug combination is evaluated in patients with pancreatic cancer. The ultimate goal is to improve treatment outcomes for patients facing this challenging disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer who have not responded to standard treatments.
Not a fit: Patients with early-stage pancreatic cancer or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promising results with similar approaches, particularly in targeting KRAS signaling in pancreatic cancer.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Kinsey, Conan — University of Utah
- Study coordinator: Kinsey, Conan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.